血清TGF-β1和VEGF水平判定吉西他滨联合卡铂治疗非小细胞肺癌患者反应性临床研究  

Serum TGF-β1 and VEGF Levels Predicting Patients Response in Gemcitabine Pluscarboplatin Treating Non-small Cell Lung Cancer

作　　者：徐佳[1] 刘爱宁[1] 严霜红 

机构地区：[1]江南大学附属医院,江苏无锡214062

出　　处：《河北医学》2016年第1期55-58,共4页Hebei Medicine

基　　金：江苏省自然科学基金青年基金项目;(编号:BK2012101)

摘　　要：目的:探讨TGF-β_1和VEGF是否可以作为非小细胞肺癌(NSCLC)患者化疗后对药物反应性的生物学标志。方法:选取我院2012年4月至2014年4月收治的58例NSCLC患者作为NSCLC组,同期健康志愿者60名为对照组。NSCLC组吉西他滨联合卡铂化疗2个疗程,化疗前后酶联免疫吸附实验(ELISA)法检测血清中TGF-β_1和VEGF水平,同时在化疗结束后评价临床疗效。结果:NSCLC组患者治疗前的血清TGF-β_1和VEGF水平明显高于对照组,差异均有统计学意义(P<0.05);化疗后,CR+PR组患者血清TGF-β_1和VEGF水平较化疗前明显降低,相反,化疗后SD+PD组患者血清TGF-β_1和VEGF水平较化疗前明显升高,差异均有统计学意义(P<0.05)。结论:非小细胞肺癌患者血清中TGF-β_1和VEGF水平升高,且治疗后TGF-β_1和VEGF变化能反映患者对吉西他滨联合卡铂化疗的反应性。Objective： To investigate whether the serum levels of transforming growth factor beta 1（ TGF-β_1） and vascular endothelial growth factor（ VEGF） are biomarkers of response to the chemotherapy.Method： A total of 118 subjects were recruited at our hospital between April 2012 and April 2014,including58 NSCLC patients receiving chemotherapy（ gemcitabine plus carboplatin）（ NSCLC group） and 60 healthy controls（ control group）.Serum TGF-β1 and VEGF levels were measured before and after chemotherapy using enzyme-linked immunosorbent assay（ ELSIA）,and the serum TGF-β1 and VEGF levels were measured when undergoing physical medical examination. The clinical efficacy was evaluated after chemotherapy. Result： Compared to control group,the serum TGF-β1and VEGF levels were significantly higher in NSCLC group before chemotherapy（ P〈0.05）. Importantly,serum TGF-β1 and VEGF levels decreased significantly after chemotherapy in CR＋PR group in comparison with before chemotherapy（ P〈0.05）. By contrast,serum TGF-β1 and VEGF levels were markedly higher after chemotherapy in the SD＋PD group in comparison with before chemotherapy（ P〈0.05）. Conclusion： The serum TGF-β1 and VEGF levels of NSCLC patients were raised,which can show the patients＇ respense to GC regimen

关 键 词：转化生长因子Β1 血管内皮生长因子 非小细胞肺癌 化疗 

分 类 号：R734.2[医药卫生—肿瘤]